Breast Neoplasms
Conditions
Brief summary
The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.
Interventions
OTHERAdvanced Practice Nurse consultation
Sponsors
Institut de Cancérologie de la Loire
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient care at the Cancer Institute Lucien Neuwirth * Patient aged over 18 years * Patient with breast cancer overexpressing HER2 adjuvant * Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital * Patient under Trastzumab subcutaneously * Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies)
Exclusion criteria
* Refusal to participate, most patient protected under guardianship. * Patient in inability to understand the course of the study * Patient with documented history of cognitive or psychiatric disorders. * Patients pregnant or lactating * Patients under guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of consultation requiring a medical advice between IPA and oncologist | 1 year | Estimate the correlation between the IPA and the oncologist about whether or not a medical opinion during the consultation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of consultations delegated to the IPA | 1 year | The oncologist estimate the percentage of consultations can be delegated to the IPA |
| Physician satisfaction questionnaire | 1 year | Physician satisfaction questionnaire of the delegation of his consultations to the IPA |
Contacts
Primary ContactMathieu ORIOL, MD
Backup ContactCécile MIGALA, IPA
Outcome results
None listed